- Home
- KURA vs PVLA Comparison
KURA vs PVLA Comparison
Compare KURA & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | PVLA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KURA | PVLA |
|---|---|---|
| Price | $11.95 | $100.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $25.00 | ★ $124.25 |
| AVG Volume (30 Days) | ★ 1.9M | 258.4K |
| Earning Date | 11-04-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,029,000.00 | N/A |
| Revenue This Year | $138.16 | N/A |
| Revenue Next Year | $67.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $11.17 |
| 52 Week High | $12.49 | $106.71 |
Technical Indicators
Market Signals| Indicator | KURA | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 63.90 |
| Support Level | $10.80 | $90.09 |
| Resistance Level | $12.32 | $106.71 |
| Average True Range (ATR) | 0.66 | 7.28 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 76.92 | 75.95 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.